I have read the Research and Markets' Privacy Policy and consent to the processing of my personal data.*

RECENTLY VIEWED PRODUCTS

TESTIMONIALS

The Service I received from the Orders and Customer Service Team was very professional. Their responses were very quick and actioned on immediately.

Mr Gueorgui TzvetanovSenior ManagerERGO Austria International AG

The Research and Markets’ customer support team provided me with timely and immediate responses and delivered exactly the information that I was looking for – great job. Thank you very much. I would recommend them to anybody who is looking for market research data.

Great customer service and super responsive. I was having issues with my payment method but Claire in customer service was super responsive to help several times until the issue was entirely resolved. Great job

Mr Detlef RethagePresidentNitto Avecia Inc

The reports ordered are of good quality and are relevant to our business needs.

Mr Etienne AdriansenSenior Director Business EvaluationLEO Pharma

Thank you for all of your help! I think your service is excellent. It is an easy platform to order interesting reports.

Mr Tomi AmberlaConsultantPöyry Management Consulting

The team at Research and Markets are first rate. Their market intelligence is relevant and accurate and the customer service fast, responsive and dependable. I always benefit from knowledge gained from their comprehensive studies and will continue to utilize their services.

Ms Liz DickinsonCEOPhysical Enterprises Inc

I have bought reports from other sources but the report that I bought from Research and Markets was the most detailed of the lot. Their customer service was excellent and I was able to get the report without any fuss.

Mr Naveed KamalAsst Manager: Business DevelopmentRangs Group Ltd

Celebrating 15
years in business
by partnering
with UNICEF for education

FEATURED COMPANIES

The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.

Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.

The analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.

Covered in this reportThe report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:- Americas- APAC- EMEA

The report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Market drivers- Exposure to risk factors- For a full, detailed list, view the full report

Market challenges- Patent expiration of top-selling drugs- For a full, detailed list, view the full report

Market trends- Emergence of targeted and combination therapies- For a full, detailed list, view the full report

Key questions answered in this report- What will the market size be in 2020 and what will the growth rate be?- What are the key market trends?- What is driving this market?- What are the challenges to market growth?- Who are the key vendors in this market space?- What are the market opportunities and threats faced by the key vendors?- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Commenting on the report, an analyst from the research team said: “A trend which is helping to boost market growth is the emergence of targeted and combination therapies. Targeted and combination therapies are being increasingly developed to treat solid tumors. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2, wherein drugs such as Kadcyla and Herceptin are administered as monotherapies or in combination. Targeting multiple pathways are known to reduce the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating solid tumors.”

According to the report, a key growth driver which is helping to boost market growth is the exposure to risk factors. Exposure to risk factors for solid tumors and the decrease in practices that reduce this risk are expected to increase the incidence of solid tumors. Solid tumors are associated with modifiable risk factors such as alcohol consumption, physical inactivity, weight gain, and obesity.

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer. The consumption of three to six glasses of alcoholic drinks per week can increase the risk of developing the disease by 15%. Also, women with estrogen-positive breast cancer who consume one glass of any alcoholic drink per day have a 90% higher risk of developing second cancer.

Further, the report states that one challenge that could hamper market growth is the patent expiration on top-selling drugs. The patent rights of most cancer drugs either have expired or are nearing their expiry date. As a result, inexpensive generic drugs are being introduced in the market. These drugs may increase the competition in the market, eventually reducing the price of key drugs. Also, patent expiries often result in loss of market exclusivity, decreasing the sales of the branded product.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.